" Plus, we are now positioned to bring back the Oral-Lyn program with the clinical development of our reformulated Oral-Lyn II that is designed to require only two sprays for glycemic control. Generex will once again be a force in diabetes, and we are happy to have ALTuCELL as an integral part of our plans.”

Does "partnering" include funding? During the CC's Joe has maintained that Oralyn hadn't been abandoned, but it was on the back burner due to other funding priorities. The partnership obviously includes use of Rapid Mist given the reformulation and "two sprays for glycemic control". Bringing Oralyn back in a viable form and use in Type I diabetes would be an exceptional accomplishment.